hims semaglutide results & Hers launched a $49 weight loss pill last week, offering a compounded version of semaglutide, the active ingredient in FDA approved drugs like Wegovy. Just 48 hours later, the company Hims: Why The Semaglutide Shortage

dbGSH: A database of S-glutathionylation

You probably have questions about how it compares to available options and whether it might be right for you

& Mwinzi, P

Morissette R, Chen W, Perritt AF, et al

It is currently under regulatory review and is not yet approved for use

The majority of patients experience significant weight regain if treatment with GLP-1 medications stops, and it is unclear if there will be a sustainable, long-term access to GLP-1 treatment for obesity for Medicare beneficiaries. Nielsen says she anticipates demand for the GLP-1 Bridge program will be high, making it important to see your healthcare provider for an evaluation now